Microbot Medical Secures Key Patent for Modular Robotic System, Expanding Market Potential to 6 Million Procedures
核心洞察
Microbot Medical (搜索) received a U.S. patent for its modular robotic surgical system, covering a base with interchangeable tool-receiver units that can be independently attached.
The patent significantly expands the potential market for the LIBERTY® system from 2.5 million to over 6 million annual endovascular procedures in the U.S.
The company's intellectual property portfolio now includes 12 patents granted globally and 57 patent applications pending for the LIBERTY® system.
Microbot Medical (搜索) Inc. has secured a significant patent from the United States Patent and Trademark Office that could dramatically expand the market potential for its LIBERTY® Endovascular Robotic System (搜索). The patent covers a modular robotic surgical system featuring a base with multiple tool-receiver units that can be independently and interchangeably attached, potentially enabling the system to address a much broader range of endovascular procedures.
Patent Expands Market Reach
The newly granted intellectual property protection allows Microbot Medical (搜索) to potentially expand its addressable market from an estimated 2.5 million peripheral endovascular procedures performed annually in the U.S. to over 6 million total endovascular procedures. This represents more than a doubling of the company's target market opportunity.
"We believe LIBERTY® is one of the most advanced and distinctive robotic systems in the world, being the first fully disposable robotic system along with other unique features such as its modular capabilities," said Harel Gadot, Chairman, CEO & President. "This patent recognizes yet another layer of our differentiation and could expand our reach to over 6 million annual endovascular procedures in the U.S. alone."
Strengthened IP Portfolio
With this latest patent grant, Microbot Medical (搜索)'s intellectual property portfolio for the LIBERTY® system now encompasses 12 patents granted globally and 57 patent applications pending. The patent supports innovation and customization capabilities that would allow the company to address different clinical indications and significantly expand its potential customer base.
The modular design covered by the patent provides the company with flexibility and protection to continue developing additional capabilities and features for the LIBERTY® system. This could enable future adaptations for a wider range of endovascular procedures beyond the peripheral market that currently represents the company's primary focus.
Regulatory Status and Commercial Plans
The LIBERTY® system remains an investigational device pending FDA 510(k) clearance and is not currently available for sale in the United States. Despite the expanded market potential, Gadot emphasized that the company's near-term focus continues to center on the peripheral market while ensuring commercial readiness plans progress as they await the FDA's regulatory decision.
Microbot Medical (搜索) positions itself as a pre-commercial stage medical technology company developing what it describes as the world's first single-use, fully disposable endovascular robotic system. The company aims to eliminate traditional barriers to accessing advanced robotic systems and improve care quality for patients and providers globally.